Sanofi SA
SAN: XPAR (FRA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| !x@ | LOCK|f&zJW | LOCK|Cg&mM?^ |
Led by Dupixent, Solid Immunology Position Helps Support Steady Long-Term Growth for Sanofi
Business Strategy and Outlook
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset upcoming patent losses.
